Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Germ Cell Tumors: early-phase trial registry

1 of 4 indexed Germ Cell Tumors trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Germ Cell Tumors: 4 US clinical trials tracked, 1 recruiting.

Germ Cell Tumors is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Hoosier Cancer Research Network, running 1 of these trials.

Enrollment posture brief

Registry condition germ-cell-tumors

OPEN 1 | RECR 25% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1

Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Germ Cell Tumors (this)25%
Open-enrollment share among volume-matched conditions near Germ Cell Tumors

Germ Cell Tumors lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Germ Cell Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Germ Cell Tumors is recruiting below its size-band peers.

    1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12Phase 21Phase 31

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Germ Cell Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Recombinant Human Thrombopoietin Drug
1 trials
Aprepitant Drug
1 trials
Bleomycin Drug
1 trials
CAR.70/IL15-transduced CB-NK cells Drug
1 trials
Ifosfamide Drug
1 trials
Paclitaxel Drug
1 trials
Fludarabine phosphate Drug
1 trials
Mesna Drug
1 trials

US sites by state

Facility locations filed on Germ Cell Tumors trials. A trial with sites in several states counts in each.

Pennsylvania 2 trials
Wisconsin 1 trials
Texas 1 trials
Tennessee 1 trials
Oregon 1 trials
New York 1 trials
New Jersey 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Germ Cell Tumors page

4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Germ Cell Tumors condition card totals 4 registered trials; most-linked intervention Recombinant Human Thrombopoietin; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.